Get started

Biotechnology

NKTR High Tight Flag- Pre-Earnings High Flyer LONGNKTR is due for earnings on August 8th. The price from the opening bell on the 7th pump nearly 100% to over $1.00 and then faded by a couple of cents. The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity action into a high tight type bull falg which is often considered to be predictive of another leg up of similar magnitude. I will be watching this in the premarket upcoming and also at the report of earnings. I hope to catch a decent ride. If I do get it I will quit the ride as soon as the indicators flip signals. This could be a good one. Buyer anticipation and sentiment could yield great profit in little time the money is exposed to the market.
NASDAQ:NKTRLong
by AwesomeAvani
3
BIOL- running earnings 8/10 LONGBIOL had a triple top in late July so this is a logical long target at 8,0, With earnings in less than two days, volumes above the mean in the past couple of days and a decent price-volume product trend coupled with a Price Monetum Oscillator without any signs of topping out in a momentum stall or fade. I see this as a long pre-earnings play with about 12% upside to the target from the current price. BIOL has no options. The last earnings were a solid cash making top and bottom line beat. Go BIOL !
BLong
by AwesomeAvani
AADI - NASDAQ PENNY Biotech pre-earnings LONGAADI has earnings in two day. On the 30 minute chart, it is significantly below the highs of May and June where it was in a wide ranged consolidation. After that in July price trended down along the support of the second lower VWAP line into a reversal on August 1 shich also ascended the VWAP lines. Upcoming earnings are in two days on the 9th. Prior two earning reports lightly beat the top and bottom lines. This small biotechnology company is making money unlike many of its cash-burning peers. The zero-lag MAC shows a line cross under the histogram which flipped red to green as the lines rise. With this confirmation, I will take a long trade into the earnings. There is no alternative in a call option in this case. From the chart, targets are 6.9, 6.9, and 8.0 over a stop loss of 5.45. I expect this trade to be finished in 4 days or less.
ALong
by AwesomeAvani
1
AMRX Biotech earnings Today LONGAMRX is a penny biotechnology stock with earnings out on the Friday the 4th. As you can see on the 15 minute chart, it took off out of consolidation on Wednesday afternoon in a burst of price volume and volatility into an ascending parallel channel. I will buy the stock in the pre-market attempting to exploit the momentum going into earnings. If there is a miss, I will quickly liquidate and instead buy put options expiring on 8/18 striking $ 5 and get as many as 100 of them. This will be a highly risky trade albeit with a comparable reward. I will position to 0.05% of my account cash balance and no more.
ALong
by AwesomeAvani
FLMD biotechology rising post earningsFLMD had earnings in May with positive earnings beating the expectation of analysts that it would continue to lose quarter after quarter. Investors and traders have reacted with a 80% run-up in the month after those earnings. On the 30-minute chart besides the consistent uptrend with minor corrections, what stands out for me is the increasing volumes relative to volumes before the last earnings report. Off the chart, I find information that insider trading with buying more shares on top of existing holdings leads me to believe that this company expects increasing revenues and sustained earnings.
NASDAQ:LFMDLong
by AwesomeAvani
EBS a biotech company focused on vaccinesEBS is a small biotechnology company whose forte is the clean processing and manufacturing facility that the FDA requires for certain bioprocessing to be certified for delivery of products to end-user patients. It is not a research facility like the one in China that accidentally released COVID and the global impact will be likely felt for another decade. EBS does depend on federal support and income from contract work from vaccine manufacturers. There is reasonable expectation or persistent and consistent revenues ongoing without fail unless the FDA decertified the facilities. On the chart, EBS is in a flat bottom triangle on its base. It is presently rising out of the triangle and towards the mean anchored VWAP It is just above The POC line which functions as dynamic support in the demand zone. I see a long trade with the stop loss below the POC line, the first target the blue line representing one standard deviation above the mean VWAP at about 9.4 while the second target is the redline two standard deviations above the mean VWAP at about 10.05 while the final target contemplates that EBS will challenge the high in May of 10.75.
NYSE:EBS
by AwesomeAvani
FULC Biotech Fib Level BouncdFULC on the 15 minute chart had a good response to favorable earnings and then retraced. It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10% price rise in the after-hours which is typically a busy trading period for biotechnology penny stocks. I will take a long trade on FULC in after hours and take off a part of the position in the next trading day and hold the rest through the weekend.
NASDAQ:FULCLong
by AwesomeAvani
VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA process, or well-received research at industry conferences and changing financials within the company. In general, they have a low beta meaning these stocks are not general market responsive and run on their own present or future merits. On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green. I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology trades long with a high R:R due to the inheret risk level.
NASDAQ:VYNE
by AwesomeAvani
VRPX Biotechnology Penny Stock Post EarningsVRPX was on a downtrend from mid-February into a reversal the beginning of May. VRPX beat earnings up still has no cash flow which is very common in this subsector. VRPX is priced on the potential of future earnings. The short and long-moving averages ratio shows bullish momentum also shows strength with an upper Bollinger Band "walk". Price has climbed over the POC line so it is higher than the mean of the share price traded for the duration of the volume profile. I see this as a risky long setup expectant of a 40% profit based on the target of the YTD high in February.
VLong
by AwesomeAvani
BLUE Biotechnology New Earnings Catalyst LONGBlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks since earnings which is about 500% annualized. GO BLUE. On the daily chart, price was above VWAP and consolidating much of last fall then dropped this YTD until the earnings report of last week. An uptrend is seen after the earnings. This has been a significant reversal sustained over the past month with price rising above the support / demand zone below it. At present, price is one standard deviation below VWAP making it undervalued and ascending. I see this as a risky long trade like many biotechology penny stocks but with a decent probability of profit in consideration of a target of 6.15 which is the top of the long term high volume area. the stop loss is just below the POC line of the volume profile at 3.15 An entry at 4.62 ( limit order above SMA200 (redlne) would yield at profit of 1.50 with a risk of 0.48 making for a R:R of 3:1. Another earnings report is coming up this week. If it is favorable, BLUE could go parabolic to hit the target in a day or two. If not, it will be time to exit the trade.
BLong
by AwesomeAvani
7
IMGN Biotech Post Earnings IMGN had great earnings the last days of April and has been trending up ever since. It is riding the upper Bollinger band consistently in this past wee. The volume spike after earnings has subsided but ongoing volume is at about 5X the moving average of early April and March. Increased volume supports price momentum. The volume spike here is obvious and significant. IMGN announced a public offering. I see this as a positive. It is primed for increasing growth but needs the fuel. Interest rates are high. Stock offering will raise cash and all shareholders will be rewarded. IMGN is resting and consolidated in a narrow range during this public offering. See also the favorable article from IBD linked below. I see IMGN as a solid swing long until the next earnings. I will watch for an uncoiling upon completion of the offering with resumption of momentum moving forward.
ILong
by AwesomeAvani
LABU Triple Leveraged Biotech Sector ETFOn the 4H Chart LABU is trending up since March 27th. Last week there was a small pullback which was met with more buying activity. On the volume indicator, the volume now is approximately 10X day by day compared with March's averages. It is this buying that is driving the bullish momentum. Small-cap speculative biotech companies are in a growth mode right now no matter adverse economic conditions for those yet to have any earnings. Big pharma is more concerned about federal attempts to further regulate prices than the economy. On the volume profile, price has ascended to above the high volume trading area on the strength of buyer interest propelling the momentum. Overall, this looks to be a decent long trade. The target is $ 9.00 the YTD high back in February.
AMEX:LABULong
by AwesomeAvani
MGRX Biotechonolgy IPO LONGMGRX a recent IPO produces a med for erectile dysfunction without FDA approval; They are basically selling a generic version of an approved medication and bypassing the patent protections and betting they will fly under the regulator radar apparatus. As might be expeted this recent nano-IPO is highlly volatile. Play with it only if you have the requisite skills to do so and only with risk capital. it does the marketing through direct to consumer telehealth services. >>>>>>>>>>>>>>>>>>See also the link below <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< On review and analysis on the 30 minute chart, the price action is squeezing down in a flat bottom triangle likely setting up a breakout upside. The RSI oscillator shows RSI crossing 50% from below. Volatility is compressing down inside the triangle for a squeeze set up. Targets are based on the supply and demand zones of the Luxalgo indicator. The first parget is the midline between the zones while the final target is just below the supply zone. As can be seen on the chart, the first target is about 100% upside while the final target is 200% upside. One of the position is closed at each target making the return 150% overall. Stop loss is below the demand zone. A stop loss is 15% yields an overall reward to risk ration of 10:1.
NASDAQ:MGRXLong
by AwesomeAvani
APLT Biotech NASDAQ Penny LONGApplied Therapeutics is an uptrending biotechnology company that has earnings in prior quarters and is heading into another earnings report about may 11th. The run up in price cction is largely on the proposition of future growth much like TSLA back in the day. On the chart besides the obvious uptrend, the volume indicator shows a dramatic volume surge compared with the running 50 day average while the MACD shows the lines above the histogram and running upward and parallel. The ideal entry would be a pullback as the price is now quite extended however I do not believe that will occur until at least after earnings. I believe this strong runner will continue until earnings unabated. As a penny stock many shares can be taken and then the position can be closed in partials along the way thus taking profits and decreasing the risk in steps. The same applies to the call options.
NASDAQ:APLT
by AwesomeAvani
1
PFE Large Cap Pharma increased its dividendPFE just raised its dividend On the chart it has been trending downward as shown also by a down sloping anchored VWAP bands. Price is currently sitting at long term support and two standard deviations below VWAP. It appears to be ready to reverse from the deep undervalued area. In confirmation, teh voume indicator shows moderate increased relative volume compared with March. I see this as a good opportunity to enter a swing long trade or investment. PFE has its increased dividend as a hint to shareholders of increasing earnings also with the next generation of COVID vaccines in the pipeline along with a diversified line of other products. The only thing that will slow PFE down in federal legislation to limit the retail MSRP prices of its products to all consumers including those with no insurance and commercial coverage outside federal programs. PFE is solid as a rock. I see the buy signal.
NYSE:PFELong
by AwesomeAvani
2
TNYA Biotechology Penny NASDAQ LONGTNYA has been in consolidation the past two days being in the flag of a bull flag pattern on the 1H chart. Earnings about six weeks ago were solid especially for a biotechnology stock which are generally priced based on future potential and not current performance. ( Fundamentally TNYA is in the gene splicing /slicing place which is perhaps the most lucrative and therapeutic of all of the various areas in the biotechnology realm. Seemingly, its potential is expodentially high. ) The zero lag MACD lines have crossed under the histogram which in general can be considered as a buy signal. The histogram has flipped to positive. Upside to the overhead resistance zone by the Luxalgo indicator is from an entry of about 5 to 6 or about 20%. Very recent high relative volume as compared with the 50 day moving average further supports a long trade at this time. The stop loss would be $.02 below the POC line of the volume profile. I will play this with options to further leverage the price action. Both options and stock are inexpensive for a small account.
NASDAQ:TNYALong
by AwesomeAvani
MGRX Biotech Penny Stock Pullback for Continuation LONGMGRX with some FDA news catalyst got a lot of action on the last session of the week. With the pullback and overwhelming volume during the session, a continuation into the upcoming week is entirely reasonable. ( see also the link) MGRX had a last price of about $1.50 about a 50% retracement from the high of the day. I will take a position at market price in the pre-market opening the week. The target will be $2.25 or midway between the current price and the high of the last session. This will represent a 50% Return on Trading Position. I will set a stop loss at $ 1.40 representing a 10% loss. Price at present is sitting on a confluence of support of both the 20 and 50 HMAs along with the lowermost VWAP band. The reward for risk is 5X. MGRX does not have options. I expect the long trade to hit the continuation target in less than 5 days. I will set a buy-stop order to take a position when the price exceeds $ 1.55 with a stop loss of $0.15 to account for the expected volatility.
NASDAQ:MGRXLong
by AwesomeAvani